Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia.
Animals
Female
Glycoproteins
/ genetics
HL-60 Cells
Hematopoiesis
Hematopoietic Stem Cells
/ metabolism
Humans
Hypoxia-Inducible Factor 1, alpha Subunit
/ genetics
Leukemia, Myeloid, Acute
/ genetics
Male
Mesenchymal Stem Cells
/ metabolism
Mice
Mice, Inbred NOD
Mice, Knockout
Mice, SCID
Neoplasm Proteins
/ genetics
U937 Cells
Adult stem cells
Hematology
Hematopoietic stem cells
Leukemias
Stem cells
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
received:
03
09
2019
accepted:
26
02
2020
pubmed:
5
5
2020
medline:
3
2
2021
entrez:
5
5
2020
Statut:
ppublish
Résumé
Acute myeloid leukemia (AML) disrupts the generation of normal blood cells, predisposing patients to hemorrhage, anemia, and infections. Differentiation and proliferation of residual normal hematopoietic stem and progenitor cells (HSPCs) are impeded in AML-infiltrated bone marrow (BM). The underlying mechanisms and interactions of residual hematopoietic stem cells (HSCs) within the leukemic niche are poorly understood, especially in the human context. To mimic AML infiltration and dissect the cellular crosstalk in human BM, we established humanized ex vivo and in vivo niche models comprising AML cells, normal HSPCs, and mesenchymal stromal cells (MSCs). Both models replicated the suppression of phenotypically defined HSPC differentiation without affecting their viability. As occurs in AML patients, the majority of HSPCs were quiescent and showed enrichment of functional HSCs. HSPC suppression was largely dependent on secreted factors produced by transcriptionally remodeled MSCs. Secretome analysis and functional validation revealed MSC-derived stanniocalcin 1 (STC1) and its transcriptional regulator HIF-1α as limiting factors for HSPC proliferation. Abrogation of either STC1 or HIF-1α alleviated HSPC suppression by AML. This study provides a humanized model to study the crosstalk among HSPCs, leukemia, and their MSC niche, and a molecular mechanism whereby AML impairs normal hematopoiesis by remodeling the mesenchymal niche.
Identifiants
pubmed: 32364536
pii: 133187
doi: 10.1172/JCI133187
pmc: PMC7260026
doi:
pii:
Substances chimiques
Glycoproteins
0
HIF1A protein, human
0
Hypoxia-Inducible Factor 1, alpha Subunit
0
Neoplasm Proteins
0
teleocalcin
76687-96-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3038-3050Subventions
Organisme : Medical Research Council
ID : FC001045
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Cancer Research UK
ID : FC001045
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0700052
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C15966/A24375
Pays : United Kingdom
Organisme : Wellcome Trust
ID : FC001045
Pays : United Kingdom
Références
Blood. 2015 Jun 18;125(25):3878-85
pubmed: 25833957
Leukemia. 2000 May;14(5):947-8
pubmed: 10803533
J Clin Invest. 2017 Feb 1;127(2):543-548
pubmed: 28067666
Blood. 2011 Nov 17;118(20):5583-92
pubmed: 21948175
Mol Cell. 2010 Oct 22;40(2):294-309
pubmed: 20965423
Leukemia. 2015 Dec;29(12):2285-95
pubmed: 26108689
Leuk Res. 2015 Oct;39(10):1034-40
pubmed: 26220865
Blood Cancer J. 2015 Apr 10;5:e302
pubmed: 25860293
Blood. 2012 May 24;119(21):4971-80
pubmed: 22490334
Leukemia. 2016 Sep;30(9):1897-908
pubmed: 27109512
Cell Stem Cell. 2018 Jun 01;22(6):879-892.e6
pubmed: 29804890
Blood. 2011 Oct 20;118(16):4431-9
pubmed: 21868571
Leukemia. 2018 Mar;32(3):575-587
pubmed: 28816238
Exp Hematol. 2018 Apr;60:40-46.e2
pubmed: 29307605
Biochem Biophys Res Commun. 2007 May 18;356(4):968-75
pubmed: 17395153
Blood. 2015 Sep 10;126(11):1302-13
pubmed: 26186938
Mol Cell Biol. 2005 Dec;25(23):10604-10
pubmed: 16287871
Nat Commun. 2018 Feb 6;9(1):519
pubmed: 29410432
Endocrinology. 2002 Mar;143(3):868-76
pubmed: 11861508
J Clin Invest. 2003 Jul;112(1):126-35
pubmed: 12840067
Nature. 2019 May;569(7755):222-228
pubmed: 30971824
Cell Stem Cell. 2010 Sep 3;7(3):391-402
pubmed: 20804974
Stem Cell Reports. 2017 Jun 6;8(6):1573-1586
pubmed: 28528702
Blood. 2013 Aug 1;122(5):749-58
pubmed: 23733335
Nature. 2009 Apr 16;458(7240):904-8
pubmed: 19212321
Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12260-5
pubmed: 11050245
Cell Stem Cell. 2014 Sep 4;15(3):365-375
pubmed: 25017722
Nature. 2013 Mar 14;495(7440):231-5
pubmed: 23434755
Nature. 2010 Aug 12;466(7308):829-34
pubmed: 20703299
Cancer Res. 2013 Feb 15;73(4):1287-97
pubmed: 23243022
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13576-81
pubmed: 23901108
Nature. 2014 Apr 10;508(7495):269-73
pubmed: 24590072
Cell Stem Cell. 2014 Jun 5;14(6):810-23
pubmed: 24905167
Cell Rep. 2017 Mar 28;18(13):3204-3218
pubmed: 28355571
Cell Stem Cell. 2012 Mar 2;10(3):259-72
pubmed: 22385654
Sci Signal. 2016 Sep 06;9(444):ra88
pubmed: 27601730
Nat Immunol. 2003 May;4(5):457-63
pubmed: 12665856
Haematologica. 2015 Jul;100(7):927-34
pubmed: 25682597
Nature. 2013 Oct 31;502(7473):637-43
pubmed: 24107994
JCI Insight. 2017 Jul 6;2(13):
pubmed: 28679949
Cell Cycle. 2009 Apr 1;8(7):1003-6
pubmed: 19270523
Blood. 2005 Jun 1;105(11):4247-54
pubmed: 15728125
Cell. 2017 Feb 23;168(5):944-945
pubmed: 28235203
Mol Ther. 2012 Feb;20(2):417-23
pubmed: 22146344
J Clin Oncol. 2012 Oct 10;30(29):3604-10
pubmed: 22965967
J Cell Biol. 2011 Nov 28;195(5):709-20
pubmed: 22123859
Haematologica. 2005 Feb;90(2):166-72
pubmed: 15710567
Cell Stem Cell. 2013 Nov 7;13(5):549-63
pubmed: 24095676
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Cell Stem Cell. 2015 Mar 5;16(3):302-13
pubmed: 25704240
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cell. 2019 Jun 13;177(7):1915-1932.e16
pubmed: 31130381
Blood Adv. 2018 Jun 26;2(12):1480-1494
pubmed: 29945938
Cell. 2007 Oct 19;131(2):324-36
pubmed: 17956733
Endocrinology. 2008 May;149(5):2403-10
pubmed: 18258678
Immunity. 2018 Apr 17;48(4):632-648
pubmed: 29669248
Blood. 2015 Apr 23;125(17):2678-88
pubmed: 25742698
Haematologica. 2018 Sep;103(9):1462-1471
pubmed: 29773599
Nat Med. 2016 Jul;22(7):812-21
pubmed: 27213817
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Cell Biol. 2017 Mar;19(3):214-223
pubmed: 28218906
Blood. 2014 Apr 24;123(17):2691-702
pubmed: 24599548
Blood. 2016 Jun 9;127(23):2841-6
pubmed: 27060169
Cell Stem Cell. 2012 Feb 3;10(2):120-36
pubmed: 22305562
Stem Cells. 2013 Sep;31(9):1902-9
pubmed: 23744828
Blood. 2016 Nov 3;128(18):2253-2257
pubmed: 27574191
Nat Cell Biol. 2017 Nov;19(11):1336-1347
pubmed: 29035359
Cancer Cell. 2017 Sep 11;32(3):324-341.e6
pubmed: 28870739
Clin Exp Metastasis. 2015 Jan;32(1):15-27
pubmed: 25391215
Science. 2008 Oct 17;322(5900):390-5
pubmed: 18927383
Stem Cell Reports. 2014 May 15;2(6):794-809
pubmed: 24936467
Stem Cells. 2009 Mar;27(3):670-681
pubmed: 19267325
Endocrinology. 2002 Sep;143(9):3681-90
pubmed: 12193584
Nature. 2016 Apr 21;532(7599):380-4
pubmed: 27074508
Blood. 2016 Dec 22;128(25):2949-2959
pubmed: 27733356
Stem Cells. 2013 Nov;31(11):2443-56
pubmed: 23922312
BMB Rep. 2012 Nov;45(11):629-34
pubmed: 23187001
Cell Stem Cell. 2008 Oct 9;3(4):416-28
pubmed: 18940733
Nature. 2012 Jan 25;481(7382):457-62
pubmed: 22281595
Mol Cell Endocrinol. 2012 Feb 26;349(2):272-80
pubmed: 22115958
Genes Dev. 2004 Nov 15;18(22):2747-63
pubmed: 15545632
J Natl Cancer Inst. 2010 Jun 2;102(11):812-27
pubmed: 20484106
Stem Cell Res. 2015 Mar;14(2):177-84
pubmed: 25665922
Mol Cell Endocrinol. 2010 Jan 15;314(1):118-27
pubmed: 19628018
Leukemia. 2016 Mar;30(3):683-91
pubmed: 26601782